Trial · NCT00697515
Outcomes17
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Permanent Product Measure of Performance (PERMP) Total Score Over the Treatment Day in the Crossover Phase | 2, 4, 8, 10, 12 and 14 hours post-dose on Day 7 | Intent to Treat (ITT) population defined as all subjects who are randomized and have at least one post-dose primary efficacy assessment. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | PERMP Total Score by Timepoint in the Crossover Phase | 2, 4, 8, 10, 12 and 14 hours post-dose on Day 7 | ITT | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | PERMP Score for the Number of Math Problems Attempted by Timepoint in the Crossover Phase | 2, 4, 8, 10, 12 and 14 hours post-dose on Day 7 | ITT | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | PERMP Score for the Number of Math Problems Answered Correctly by Timepoint in the Crossover Phase | 2, 4, 8, 10, 12 and 14 hours post-dose on Day 7 | ITT | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale With Prompts (ADHD-RS) Total Score at up to 28 Days in the Dose Optimization Phase | Baseline and 7, 14, 21 and 28 days | Enrolled Efficacy Population (EEP) defined as all subjects who have taken one dose of study medication in the Dose Optimization Phase and had one post-Baseline efficacy assessment. | Units on a scale | MEAN |
| SECONDARY | ADHD-RS With Prompts Total Score in the Crossover Phase | 7 days | ITT | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Assessment of Clinical Global Impression-Severity of Illness (CGI-S) in the Dose Optimization Phase | Baseline | EEP | Participants | NUMBER |
| SECONDARY | Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) in the Dose Optimization Phase | 7, 14, 21 and 28 days | EEP | Participants | NUMBER |
| SECONDARY | Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) in the Crossover Phase | 7 days | ITT | Participants | NUMBER |
| SECONDARY | Change From Baseline in the Brown Attention Deficit Disorder Scale (BADDS) Total Scores at 26 Days in the Dose Optimization Phase | Baseline and 26 days | EEP | Units on a scale | MEAN |
| SECONDARY | Level of Satisfaction With Study Treatment on Medication Satisfaction Questionnaire (MSQ) in the Dose Optimization Phase | 26 days | EEP | Participants | NUMBER |
| SECONDARY | Change From Baseline in Adult ADHD Impact Module (AIM-A) Question 1 Score at 26 Days in the Dose Optimization Phase | Baseline and 26 days | EEP | Units on a scale | MEAN |
| SECONDARY | Change From Baseline in AIM-A Question 4 Score at 26 Days in the Dose Optimization Phase | Baseline and 26 days | Units on a scale | MEAN | |
| SECONDARY | Change From Baseline in Systolic Blood Pressure at Up to 28 Days in the Dose Optimization Phase | Baseline and 7, 14, 21 and 28 days | Safety Population (SP) defined as all subjects who received at least one dose of study medication. | mmHg | MEAN |
| SECONDARY | Change From Baseline in Diastolic Blood Pressure at Up to 28 Days in the Dose Optimization Phase | Baseline and 7, 14, 21 and 28 days | SP | mmHg | MEAN |
| SECONDARY | Change From Baseline in Pulse Rate at Up to 28 Days in the Dose Optimization Phase | Baseline and 7, 14, 21 and 28 days | SP | bpm | MEAN |
| SECONDARY | Change From Baseline in Electrocardiogram Results (QTcF Interval) at 7 Days in the Crossover Phase | Baseline and 7 days | SP | msec | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00697515/outcomes